O
IONS icon

OppenheimerFunds’s Ionis Pharmaceuticals IONS Stock Holding History

OppenheimerFunds’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$165M Buy
2,027,449
+7,323
+0.4% +$472K 0.2% 113
2018
Q4 		$109M Sell
2,020,126
-47,474
-2% -$2.42M 0.16% 142
2018
Q3 		$107M Sell
2,067,600
-864,450
-29% -$40.6M 0.12% 183
2018
Q2 		$122M Buy
2,932,050
+57,025
+2% +$2.53M 0.15% 166
2018
Q1 		$127M Buy
2,875,025
+185,044
+7% +$9.4M 0.16% 152
2017
Q4 		$135M Sell
2,689,981
-18,426
-0.7% -$1.01M 0.16% 153
2017
Q3 		$137M Sell
2,708,407
-25,111
-0.9% -$1.32M 0.17% 145
2017
Q2 		$139M Buy
2,733,518
+10,418
+0.4% +$485K 0.17% 152
2017
Q1 		$109M Sell
2,723,100
-406
-0% -$18.2K 0.13% 177
2016
Q4 		$130M Buy
2,723,506
+529,880
+24% +$21M 0.16% 155
2016
Q3 		$80.4M Buy
2,193,626
+307,175
+16% +$9.61M 0.1% 233
2016
Q2 		$43.9M Buy
1,886,451
+437,260
+30% +$14.1M 0.06% 344
2016
Q1 		$58.7M Buy
1,449,191
+178,870
+14% +$7.27M 0.08% 272
2015
Q4 		$78.7M Buy
+1,270,321
New +$68.5M 0.1% 221

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OppenheimerFunds's IONS Position: Q1 2019 in Review

OppenheimerFunds increased its Ionis Pharmaceuticals (IONS) stake by 0.36% in Q1 2019, buying an estimated $472K and bringing the position to 2,027,449 shares worth $165M. The position accounts for 0.2% of the portfolio, ranked #113.

OppenheimerFunds first reported a position in IONS in Q4 2015 and has held it in 14 quarters since. 393 funds tracked by Wall St. Rank hold IONS as of Q1 2019.

  • OppenheimerFunds held 2,027,449 shares of Ionis Pharmaceuticals worth $165M as of Q1 2019.
  • OppenheimerFunds bought 7,323 Ionis Pharmaceuticals shares in Q1 2019, an estimated $472K.
  • Ionis Pharmaceuticals made up 0.2% of OppenheimerFunds's portfolio in Q1 2019, its #113 holding.
  • OppenheimerFunds first reported a position in Ionis Pharmaceuticals in Q4 2015 and has held it in 14 quarters since.
  • 393 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2019.

Based on OppenheimerFunds's 13F filing for Q1 2019, filed 13 May 2019.